Axsome Therapeutics, Inc. (AXSM) Income Statement

Sequential growth has remained consistently strong across the ten-quarter window, which points to volume-driven expansion rather than a one-off stocking event. The deceleration from peak growth rates above 80% in 2024 to roughly 50% in 2026 is expected as the revenue base grows, but investors should monitor whether prescription trends continue to support this pace.

The stability of gross margin despite rapid revenue scaling suggests the variable cost of goods is negligible and that pricing has not required material concessions. This structural advantage means that operating profitability depends almost entirely on the trajectory of fixed operating expenses rather than on unit economics.

Operating income is clearly scaling faster than gross profit in percentage terms, which is the expected signature of operating leverage. However, the absolute operating loss remains negative and SG&A continues to absorb roughly 84% of gross profit, so the inflection to sustained profitability has not yet been demonstrated in the reported figures.

The cost structure reflects a deliberate weighting toward commercialization of Auvelity and Sunosi, which is consistent with a launch-phase biotech. Investors should watch whether SG&A growth begins to decelerate relative to revenue, since that would confirm the fixed sales force is being amortized over a larger base.